OBJECTIVES: Methohexital, a barbiturate anesthetic commonly used for electroconvulsive therapy (ECT), possesses dose-dependent anticonvulsant properties, and its use can interfere with effective seizure therapy in patients with high seizure thresholds. Ketamine, an N-methyl-d-aspartate antagonist with epileptogenic properties not broadly used for ECT inductions, is a commonly used induction agent for general anesthesia. Recent studies suggest that the use of ketamine is effective in allowing successful ECT treatment in patients with high seizure thresholds without an increase in adverse effects. In this preliminary study, we directly compared the recovery and reorientation times of subjects receivingketamine and methohexital for ECTs. METHODS:Twenty patients were randomized in a crossover design to receive methohexital and ketamine for ECT inductions in alternating fashion in 6 trials. Primary outcome measures were recovery time (voluntary movement, respiratory effort, blood pressure, consciousness, and O2 saturation) and reorientation time. Secondary outcome measures were individual recovery variables, adverse effect occurrence, and seizure duration. RESULTS:Overall recovery time was not significantly different between the 2 treatment arms (F(1, 17) = 0.72; P = 0.41). Reorientation time was faster in the methohexital arm (F(1, 17) = 9.23; P = 0.007). CONCLUSION:Ketamine inductions resulted in higher number of adverse effects, higher subject dropout rates, and a longer reorientation time with respect to methohexital inductions. No significant difference in postanesthesia recovery time was found between the ketamine and methohexital arms. Intolerability to ketamine affected a significant proportion of subjects and suggests that ketamine should remain as an alternative or adjunctive agent for patients with high seizure thresholds.
RCT Entities:
OBJECTIVES:Methohexital, a barbiturate anesthetic commonly used for electroconvulsive therapy (ECT), possesses dose-dependent anticonvulsant properties, and its use can interfere with effective seizure therapy in patients with high seizure thresholds. Ketamine, an N-methyl-d-aspartate antagonist with epileptogenic properties not broadly used for ECT inductions, is a commonly used induction agent for general anesthesia. Recent studies suggest that the use of ketamine is effective in allowing successful ECT treatment in patients with high seizure thresholds without an increase in adverse effects. In this preliminary study, we directly compared the recovery and reorientation times of subjects receiving ketamine and methohexital for ECTs. METHODS: Twenty patients were randomized in a crossover design to receive methohexital and ketamine for ECT inductions in alternating fashion in 6 trials. Primary outcome measures were recovery time (voluntary movement, respiratory effort, blood pressure, consciousness, and O2 saturation) and reorientation time. Secondary outcome measures were individual recovery variables, adverse effect occurrence, and seizure duration. RESULTS: Overall recovery time was not significantly different between the 2 treatment arms (F(1, 17) = 0.72; P = 0.41). Reorientation time was faster in the methohexital arm (F(1, 17) = 9.23; P = 0.007). CONCLUSION:Ketamine inductions resulted in higher number of adverse effects, higher subject dropout rates, and a longer reorientation time with respect to methohexital inductions. No significant difference in postanesthesia recovery time was found between the ketamine and methohexital arms. Intolerability to ketamine affected a significant proportion of subjects and suggests that ketamine should remain as an alternative or adjunctive agent for patients with high seizure thresholds.
Authors: Keith G Rasmussen; Simon Kung; Maria I Lapid; Tyler S Oesterle; Jennifer R Geske; Gregory A Nuttall; William C Oliver; John P Abenstein Journal: Psychiatry Res Date: 2013-12-21 Impact factor: 3.222
Authors: Andrew D Krystal; Richard D Weiner; Margaret D Dean; Virginia H Lindahl; Louis A Tramontozzi; Grace Falcone; C Edward Coffey Journal: J Neuropsychiatry Clin Neurosci Date: 2003 Impact factor: 2.198
Authors: Liam Trevithick; R Hamish McAllister-Williams; Andrew Blamire; Tim Branton; Ross Clark; Darragh Downey; Graham Dunn; Andrew Easton; Rebecca Elliott; Clare Ellwell; Katherine Hayden; Fiona Holland; Salman Karim; Jo Lowe; Colleen Loo; Rajesh Nair; Timothy Oakley; Antony Prakash; Parveen K Sharma; Stephen R Williams; Ian M Anderson Journal: BMC Psychiatry Date: 2015-10-21 Impact factor: 3.630
Authors: Ian M Anderson; Andrew Blamire; Tim Branton; Ross Clark; Darragh Downey; Graham Dunn; Andrew Easton; Rebecca Elliott; Clare Elwell; Katherine Hayden; Fiona Holland; Salman Karim; Colleen Loo; Jo Lowe; Rajesh Nair; Timothy Oakley; Antony Prakash; Parveen K Sharma; Stephen R Williams; R Hamish McAllister-Williams Journal: Lancet Psychiatry Date: 2017-03-27 Impact factor: 27.083